Showing 271-280 of 2319 results for "".
Rosacea: A Closer Look at the Latest Treatment Options
https://practicaldermatology.com/topics/acne-rosacea/rosacea-a-closer-look-at-the-latest-treatment-options/23983/The latest treatments and expanded, responsible choices for treating patients with rosacea.Tips for Success with Fillers
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/tips-for-success-with-fillers/20149/Heidi Waldorf, MD offers tips for getting the best results possible with fillers. From how to evaluate what patients need to considering shapes and proportions, she offers hands-on advice to help achieve optimal outcomes. Plus, she discusses the importance of managing patient expectations.Identifying SCC Risk
https://practicaldermatology.com/topics/skin-cancer-photoprotection/identifying-scc-risk/20144/Sherrif Ibrahim, MD discusses the challenges of managing squamous cell carcinoma (SCC). Great steps have been made in clinical, pathological staging systems, but Dr. Ibrahim says it’s still difficult to determine what to do with borderline cases. He talks about the need to determine frequency and inDermWireTV: Zoryve Approved; New SDPA President; Project Determi-Nation; Stelara for Pediatric PsA
https://practicaldermatology.com/topics/psoriasis/dermwiretv-zoryve-approved-new-sdpa-president-project-determi-nation-stelara-for-pediatric-psa/20115/FDA has approved Zoryve from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The novel formulation of roflumilast cream 0.3% is indicated for once-daily application. Stelara (ustekinumab) from Janssen is now approveDermWireTV: Opzelura for Vitiligo; Biosimilars Boom; Updates from BTL and Cynosure; DIS Launch
https://practicaldermatology.com/topics/psoriasis/dermwiretv-opzelura-for-vitiligo-biosimilars-boom-updates-from-btl-and-cynosure-dis-launch/20109/FDA has approved Opzelura (ruxolitinib cream 1.5%, Incyte) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Analysts predict that use of biosimilars in the US is about to increase significantly as Humira (adalimumab, AbbVie) faces patent eDermatologists Give AI A Thumbs Up
https://practicaldermatology.com/topics/practice-management/dermatologists-give-ai-a-thumbs-up/23673/Dr. Vishal Patel talks augmented intelligence and how it may change practice.Hair Care Trends You Need to Know
https://practicaldermatology.com/conferences/aad-summer-2021/hair-care-trends-you-need-to-know/19976/People are sharing more than their latest dance moves on TikTok. Many—with no background in science—are dispensing hair care advice, some of which could even be dangerous. Learn which trends you should know about in order to educate your patients about what really works versus what could do more harKeloids: To Cut or Not to Cut
https://practicaldermatology.com/topics/skin-cancer-photoprotection/keloids-to-cut-or-not-to-cut/19987/When treating keloids, ask patients what they want to achieve. Are they hoping to decrease itch or pain? Do they want to flatten or soften the appearance of a keloid? Hilary Baldwin, MD reviews her approach to deciding whether to remove a keloid surgically as well as other treatment options. Plus, sDermWireTV: Soliton's Resonic Launch, Natroba for Scabies, UV Safety
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-solitons-resonic-launch-natroba-for-scabies-uv-safety/19938/Skin Cancer awareness month provides an opportunity for dermatologists to double down on patient outreach as the AAD launches the “Skin Cancer, Take a Hike” steps challenge. Soliton’s Rapid Acoustic Pulse Device launches under the name Resonic. Natroba (Spinosad) Topical Suspension from ParaPRO is nEye Opener
https://practicaldermatology.com/programs/practical-dermatology/eye-opener/19918/From each individual's implicit bias to the systemic bias that influences the tools of research and clinical practice, innumerable factors go into every patient encounter. Only individuals who are open to recognizing and confronting bias can overcome it. Panelists share their personal perspectives o